Breast cancer is a complex disease with intrinsic or molecular subtypes including HR+, HER2-enriched, and triple negative. In the last decade, CDK4/6 inhibitors rapidly became the standard of care in the metastatic HR+/HER2- breast cancer setting. The landscape continues to evolve with these agents moving into the adjuvant setting and novel SERDS entering Phase III trials. More recently, HER2-targeted agents including ADCs were approved for later lines of HER2+ disease and have started to be evaluated in the adjuvant setting. In the past two years, landmark approvals of targeted therapies and immune-therapies (IO) have been incorporated into treatment algorithms of metastatic TNBC, an area of high unmet need with few therapeutic options outside of chemotherapy. IO combinations are also being evaluated in registrational trials in the neo/adjuvant setting in all three subtypes of breast cancer with significant potential to transform each landscape.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Breast Cancer to help guide strategic and tactical commercial development decisions for market participants.
